Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 2/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937193 | 1.00 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL12867066 | 1.00 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL717531 | 0.79 | — | — | |
| SCHEMBL12867077 | 0.77 | APOBEC3A (0.31) | APOBEC3AAPOBEC3G | |
| SCHEMBL719071 | 0.75 | ALDH1A1 (0.42) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL1172087 | 0.71 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL14215599 | 0.71 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL24496767 | 0.67 | ALDH1A1 (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL456066 | 0.67 | ALDH1A1 (0.40) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB | |
| SCHEMBL11509455 | 0.67 | APOBEC3A (0.37) | APOBEC3AAPOBEC3GALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110040120-A1 | PREPARATION OF OSELTAMIVIR PHOSPHATE (TAMIFLU®) AND INTERMEDIATES STARTING FROM D-GLUCOSE OR D-XYLOSE | APOTEX PHARMACHEM INC. (CA) | 2011-02-17 | — | — | US | disclosed |
| US-20080009639-A1 | Preparation of oseltamivir phosphate (Tamiflu) and intermediates starting from D-glucose or D-xylose | APOTEX PHARMACHEM INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040120-A1 | PREPARATION OF OSELTAMIVIR PHOSPHATE (TAMIFLU®) AND INTERMEDIATES STARTING FROM D-GLUCOSE OR D-XYLOSE | G6PD, GALE, MGAM | APOBEC3A 242/4885APOBEC3G 212/4885ALDH1A1 1478/4885 |
| US-20080009639-A1 | Preparation of oseltamivir phosphate (Tamiflu) and intermediates starting from D-glucose or D-xylose | G6PD, GALE, MGAM | APOBEC3A 337/4885APOBEC3G 298/4885ALDH1A1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.